1. Home
  2. BMY
  3. BMY News

Latest Bristol-Myers Squibb Company (BMY) News on September 4, 2025

Healthcare Industry Veteran Scott Rairigh Joins Psilera to Lead Corporate Development
BMY

PR Newswire

4 hours ago

Healthcare Industry Veteran Scott Rairigh Joins Psilera to Lead Corporate Development

2 Top Dividend Stocks to Buy With Less Than $50
BMY

Motley Fool

4 hours ago

2 Top Dividend Stocks to Buy With Less Than $50

3 Things You Need to Know if You Buy Pfizer Today
BMY

Motley Fool

5 hours ago

3 Things You Need to Know if You Buy Pfizer Today

BMY

MT Newswires

9 hours ago

Bristol Myers Squibb Insider Sold Shares Worth $2,650,480, According to a Recent SEC Filing

How Is Bristol-Myers’ Stock Performance Compared to Other Pharma Stocks?
BMY

Barchart

9 hours ago

How Is Bristol-Myers’ Stock Performance Compared to Other Pharma Stocks?

2 Large-Cap Stocks Worth Your Attention and 1 We Brush Off
BMY

StockStory

11 hours ago

2 Large-Cap Stocks Worth Your Attention and 1 We Brush Off

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
BMY

Zacks

a day ago

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?
BMY

Simply Wall St.

a day ago

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?

Cytokinetics Stock Jumps. The Biotech’s Heart Drug Wows.
BMY

Barrons.com

2 days ago

Cytokinetics Stock Jumps. The Biotech’s Heart Drug Wows.

Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
BMY

Zacks

2 days ago

Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?

BMY

MT Newswires

2 days ago

Agilent Says Colorectal Cancer Test Gets European IVDR Certification as Companion Diagnostic

SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025
BMY

PR Newswire

2 days ago

SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025

Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital
BMY

Insider Monkey

2 days ago

Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
BMY

Zacks

3 days ago

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

BMO Capital Maintains a Hold on Bristol-Myers Squibb (BMY)
BMY

Insider Monkey

4 days ago

BMO Capital Maintains a Hold on Bristol-Myers Squibb (BMY)

Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease
BMY

Investor's Business Daily

5 days ago

Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease

Investors three-year losses continue as Bristol-Myers Squibb (NYSE:BMY) dips a further 3.2% this week, earnings continue to decline
BMY

Simply Wall St.

6 days ago

Investors three-year losses continue as Bristol-Myers Squibb (NYSE:BMY) dips a further 3.2% this week, earnings continue to decline

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
BMY

Business Wire

6 days ago

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
BMY

Business Wire

6 days ago

Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

BioNTech SE (BNTX) Teams Up with BMS in $11B Cancer Deal
BMY

Insider Monkey

7 days ago

BioNTech SE (BNTX) Teams Up with BMS in $11B Cancer Deal

Cantor Fitzgerald Cuts Bristol-Myers (BMY) Price Target, Keeps Neutral
BMY

Insider Monkey

7 days ago

Cantor Fitzgerald Cuts Bristol-Myers (BMY) Price Target, Keeps Neutral

Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
BMY

Zacks

8 days ago

Will Camzyos Strengthen BMY's Cardiovascular Portfolio?

How Investors May Respond To ACADIA Pharmaceuticals (ACAD) Hiring an Industry Veteran for Growth Strategy
BMY

Simply Wall St.

8 days ago

How Investors May Respond To ACADIA Pharmaceuticals (ACAD) Hiring an Industry Veteran for Growth Strategy

Redwire Corporation (RDW): A Bull Case Theory
BMY

Insider Monkey

8 days ago

Redwire Corporation (RDW): A Bull Case Theory

Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)
BMY

StockStory

9 days ago

Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)

1 Profitable Stock Worth Investigating and 2 We Turn Down
BMY

StockStory

9 days ago

1 Profitable Stock Worth Investigating and 2 We Turn Down

Scenic Enters License and Research Agreement with Alnylam
BMY

GlobeNewswire

9 days ago

Scenic Enters License and Research Agreement with Alnylam

RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?
BMY

Zacks

10 days ago

RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

[Latest] Global Targeted Drug Delivery Market Size/Share Worth USD 39.6 Billion by 2034 at a 15.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
BMY

GlobeNewswire

10 days ago

[Latest] Global Targeted Drug Delivery Market Size/Share Worth USD 39.6 Billion by 2034 at a 15.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
BMY

Business Wire

10 days ago

Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025

Should You Revisit Bristol-Myers Squibb Amid Uncertainty Over Pharma Tariffs in 2025?
BMY

Simply Wall St.

10 days ago

Should You Revisit Bristol-Myers Squibb Amid Uncertainty Over Pharma Tariffs in 2025?

Bristol-Myers Squibb Company (NYSE:BMY) is favoured by institutional owners who hold 82% of the company
BMY

Simply Wall St.

12 days ago

Bristol-Myers Squibb Company (NYSE:BMY) is favoured by institutional owners who hold 82% of the company

BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
BMY

Zacks

13 days ago

BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?

Does Cobenfy Have the Potential to Become a Top Drug for BMY?
BMY

Zacks

15 days ago

Does Cobenfy Have the Potential to Become a Top Drug for BMY?

BMY

MT Newswires

15 days ago

Agilent Technologies Says US FDA Approves its Colorectal Cancer Test as Companion Diagnostic

Supply-Chain Tech Firm Overhaul Raises $105 Million
BMY

The Wall Street Journal

15 days ago

Supply-Chain Tech Firm Overhaul Raises $105 Million

FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug
BMY

Pharmaceutical Technology

15 days ago

FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?
BMY

Zacks

16 days ago

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
BMY

Zacks

16 days ago

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb
BMY

Business Wire

17 days ago

FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb

BMY

MT Newswires

17 days ago

Bristol-Myers Squibb, SystImmune Get Breakthrough Therapy Designation for Lung Cancer Treatment

The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific
BMY

Zacks

17 days ago

The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
BMY

PR Newswire

17 days ago

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Biopharma layoffs rise as drugmakers tighten belts and reorganize
BMY

Pharma Voice

17 days ago

Biopharma layoffs rise as drugmakers tighten belts and reorganize

Bristol Myers (BMY) Partners with Bain Capital to Create Immunology Therapies
BMY

Insider Monkey

18 days ago

Bristol Myers (BMY) Partners with Bain Capital to Create Immunology Therapies

BMY

Morningstar Research

20 days ago

Analyst Report: Bristol-Myers Squibb Company

Top Research Reports for Lowe's, Bristol-Myers & Marvell Technology
BMY

Zacks

20 days ago

Top Research Reports for Lowe's, Bristol-Myers & Marvell Technology

AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
BMY

Zacks

20 days ago

AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs

Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.
BMY

Barrons.com

20 days ago

Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.

Exelixis Gains 15.6% YTD: How Should You Play the Stock?
BMY

Zacks

21 days ago

Exelixis Gains 15.6% YTD: How Should You Play the Stock?

PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?
BMY

Zacks

22 days ago

PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?

Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
BMY

Zacks

22 days ago

Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?

Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
BMY

Zacks

22 days ago

Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?

BMY

MT Newswires

22 days ago

Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $55, Maintains Neutral Rating

Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks
BMY

Motley Fool

22 days ago

Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
BMY

ACCESS Newswire

22 days ago

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution

Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions
BMY

StockStory

22 days ago

Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions

BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook
BMY

StockStory

22 days ago

BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook

Editas Medicine Announces Second Quarter 2025 Results and Business Updates
BMY

GlobeNewswire

23 days ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

BMY

Energy Global

23 days ago

Simtel and VERBUND to build photovoltaic park in Romania

2025 Japan Residential Water Treatment Systems Market Report | Now Available
BMY

GlobeNewswire

23 days ago

2025 Japan Residential Water Treatment Systems Market Report | Now Available

American Kidney Fund’s Kidney Health for All Health Equity Program Launches New Resources for Patients and Health Care Professionals
BMY

GlobeNewswire

23 days ago

American Kidney Fund’s Kidney Health for All Health Equity Program Launches New Resources for Patients and Health Care Professionals

Cash held by US companies halved since 2021 amid high interest rates, data shows
BMY

Reuters

23 days ago

Cash held by US companies halved since 2021 amid high interest rates, data shows

Mutual Funds Can't Get Enough Nvidia Stock, Google. Here's Why.
BMY

Investor's Business Daily

23 days ago

Mutual Funds Can't Get Enough Nvidia Stock, Google. Here's Why.

DraftKings price target raised to $55 from $45 at Argus
BMY

TipRanks

23 days ago

DraftKings price target raised to $55 from $45 at Argus

Defense Stock Breaks Out After Earnings, Analyst Upgrade
BMY

Investor's Business Daily

23 days ago

Defense Stock Breaks Out After Earnings, Analyst Upgrade

ACHR: Archer Aviation Stock Tumbles as Q2 Loss Nearly Doubles
BMY

GuruFocus.com

23 days ago

ACHR: Archer Aviation Stock Tumbles as Q2 Loss Nearly Doubles

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
BMY

GlobeNewswire

23 days ago

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth
BMY

GlobeNewswire

24 days ago

Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth

Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations
BMY

GlobeNewswire

24 days ago

Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations

Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.
BMY

Barrons.com

24 days ago

Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.

C3.ai's Generative AI Surge: A Catalyst for Fiscal 2026 Upside?
BMY

Zacks

a month ago

C3.ai's Generative AI Surge: A Catalyst for Fiscal 2026 Upside?

The Strong Earnings Posted By Bristol-Myers Squibb (NYSE:BMY) Are A Good Indication Of The Strength Of The Business
BMY

Simply Wall St.

a month ago

The Strong Earnings Posted By Bristol-Myers Squibb (NYSE:BMY) Are A Good Indication Of The Strength Of The Business

BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
BMY

Zacks

a month ago

BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?

5% Yields Are Hard to Find. Here Are 4 Dividend Stocks You Can Count On.
BMY

Barrons.com

a month ago

5% Yields Are Hard to Find. Here Are 4 Dividend Stocks You Can Count On.

Pfizer Pops Despite Looming Pharma Tariffs
BMY

The Daily Upside

a month ago

Pfizer Pops Despite Looming Pharma Tariffs

Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth
BMY

Zacks

a month ago

Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth

Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
BMY

Zacks

a month ago

Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
BMY

Zacks

a month ago

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO
BMY

BioPharma Dive

a month ago

Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO

BMY

MT Newswires

a month ago

Daiwa Securities Downgrades Bristol-Myers Squibb to Neutral From Outperform, Adjusts PT to $42 From $60

BMY

MT Newswires

a month ago

Bristol-Myers Squibb Says FDA Grants Priority Review to Cancer Drug

Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMY

Business Wire

a month ago

Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
BMY

Zacks

a month ago

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped.
BMY

Barrons.com

a month ago

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped.

J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
BMY

Zacks

a month ago

J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
BMY

CNW Group

a month ago

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
BMY

GlobeNewswire

a month ago

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time
BMY

The Wall Street Journal

a month ago

Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time

Bristol-Myers Squibb Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
BMY

Simply Wall St.

a month ago

Bristol-Myers Squibb Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

BMY

Morningstar Research

a month ago

Analyst Report: Bristol-Myers Squibb Company

BMY

MT Newswires

a month ago

UBS Adjusts Price Target on Bristol-Myers Squibb to $46 From $52, Maintains Neutral Rating

BMY

MT Newswires

a month ago

BMO Capital Adjusts Price Target on Bristol-Myers Squibb to $47 From $53, Maintains Market Perform Rating

BMY

MT Newswires

a month ago

Citigroup Adjusts Price Target on Bristol-Myers Squibb to $47 From $51, Maintains Neutral Rating

BMY

MT Newswires

a month ago

Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $51 From $56, Maintains Neutral Rating

BMY

MT Newswires

a month ago

Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Maintains Outperform Rating

BMY

MT Newswires

a month ago

JPMorgan Cuts Price Target on Bristol-Myers Squibb to $65 From $67, Maintains Overweight Rating

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?
BMY

Simply Wall St.

a month ago

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?

Stock Index Futures Plunge on Trump’s Tariffs & A Weak US Jobs Report
BMY

Barchart

a month ago

Stock Index Futures Plunge on Trump’s Tariffs & A Weak US Jobs Report

BMY

Morningstar Research

a month ago

Analyst Report: Bristol-Myers Squibb Company

Share on Social Networks: